-
What will it take to drive down the number of chlamydia infections in young women? While routine chlamydia screening is recommended for all sexually active females age 24 years and younger, only about half (49.9%) were screened during 2008-09, according to data collected in more than 1,000 U.S. health plans.
-
When HIV is not diagnosed until women go into labor, their infants usually are treated soon after birth with the antiretroviral drug zidovudine to prevent infant infection.
-
Amphora, under development by Evofem of San Diego, is a bioadhesive acid-buffering gel that coats the vaginal wall and cervix. Amphora helps maintain a woman's natural pH level between 3.8 and 4.2.
-
Trichomoniasis is the most common curable sexually transmitted infection (STI) in young, sexually active women, according to the Centers for Disease Control and Prevention. An estimated 7.4 million new cases occur each year in U.S. women and men.
-
Four hundred thousand (1.6% of U.S. adolescents) experience serious physical and/or sexual dating violence each year.
-
Since results of the 2002 Women's Health Initiative (WHI) report suggested that use of menopausal hormone therapy increases risk of coronary heart disease, science has examined the timing of therapy initiation on safe use of such treatment.
-
Is your facility participating in National HIV Testing Day on June 27? If not, you may be missing an important community outreach opportunity to help people learn their HIV status.
-
The investigators prospectively enrolled and followed a cohort of 97 teens before and six, 12, and 18 months after starting DMPA.
-
Since its introduction in 2009, use of the non-latex FC2 Female Condom (Women's Health Co., Chicago) has grown.
-
What is your facility's policy on providing multiple pill packs? Results of a new study might make you rethink your strategy.
